The medicinal value of cantharidin-producing Blister Beetles (Meloidae) and their industrialization

Blister beetles occupy a distinctive position among medicinal insects owing to their ability to produce cantharidin, a bioactive compound with potent antitumor activity. This effect is primarily mediated through the inhibition of protein phosphatases, and its well-characterized molecular mechanism, together with its amenability to structural modification, renders cantharidin an important scaffold for drug development. Globally, blister beetles have been widely utilized in the treatment of diverse conditions, including cancer, dermatological disorders, and sexual dysfunction. Currently, pharmaceutical products derived from cantharidin and its analogues constitute a relatively well-established therapeutic system, exemplified by formulations such as Aidi injection and norcantharidin tablets. Despite these advances, the large-scale artificial rearing of blister beetles remains a major bottleneck, primarily due to the obligate dependence of larvae on grasshopper eggs as a food source. Although progress has been achieved in the development of artificial diets, these formulations are still unable to fully substitute natural feeding substrates. Future research should prioritize elucidation of the cantharidin biosynthetic pathway and its integration with synthetic biology strategies, optimization of in vivo collection methods, and the development of semi-natural rearing systems. These efforts will be essential to enable the sustainable utilization and industrial-scale production of blister beetle resources.